Another Johnson & Johnson talcum powder lawsuit went to trial this week, as the Missouri 22nd Circuit Court in St. Louis empaneled a jury to hear a case filed on behalf of 22 women who claim the company’s Baby Powder and Shower-to-Shower products contributed to their ovarian cancer.
The case, Ingham, et al. v. Johnson & Johnson, et al. (No. 1522-CC1041), names just one plaintiff from Missouri. The remaining 21 are residents of other states.
Jury selection in the case began on Monday. The trial is expected to last roughly 6 weeks.
As is the case with more than 7,000 similar claims pending in courts throughout the United States, plaintiffs allege that Johnson & Johnson was aware of scientific evidence linking the regular, repeated application of talc-based powders to the female genitals to an increased risk of ovarian cancer. They further allege that Johnson & Johnson declined to warn consumers of this possible risk in order to protect sales of Baby Powder and Shower-to-Shower.
Missouri’s 22nd Circuit is home to one of the nation’s larger talcum powder litigations, and has been convening trials since February 2015:
The $72 million verdict was eventually dismissed to comply with new standards set by the U.S. Supreme Court’s recent ruling in Bristol-Myers Squibb v. Superior Court of California, which held that plaintiffs must file suit in jurisdictions where defendants are headquartered or where their injuries occurred.
However, the $110 million verdict was upheld, after the trial court concluded that jurisdiction was appropriate because Johnson & Johnson had used a Missouri-based company to label, package and distribute their talc products.
Johnson & Johnson is appealing the other Missouri verdicts that were awarded to other out-of-state talcum powder plaintiffs.